Navigation Links
Nexavar Data to be Presented at 46th American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

ination with Capecitabine in Patients with Advanced Breast Cancer.
  • Patricia Gomez, M.D., Breast Cancer Center, Vall d'Hebron University Hospital, Barcelona, Spain
  • Abstract 1083, General Poster Session, Breast Cancer Track
  • Saturday, June 5, 2010, 2:00-6:00 p.m., S Hall A2

"With more than 70 investigator and company sponsored studies being presented at ASCO, we look forward to continuing our work with investigators to understand how Nexavar may fit into other areas of the therapeutic landscape, particularly with respect to how biomarkers status may guide selection of therapy, which is a step toward personalized medicine," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals.  

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 90 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by other companies, international study groups, government agencies a
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
2. Bayer and Onyx Announce Nexavar Data Presentations at 44th American Society of Clinical Oncology Annual Meeting
3. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
4. Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting
5. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
9. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
10. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
11. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... , March 29, 2015  Caris Life ... in which Caris Molecular Intelligence®, the company,s panomic, ... and differences between several rare and difficult to ... that have the potential to improve patient outcomes. ... B at the Society of Gynecologic Oncology (SGO) ...
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) ... and high prices in 2008. However, the situation has ... on gaining momentum now. , To date, the world ... 100,000 thousand tonnes. No considerable growth was registered in ... rocketed during 2012-2013, registering 11% growth as against the ...
(Date:3/27/2015)... Working in collaboration with the National Amyloidosis Centre at ... Richmond Pharmacology is the first centre worldwide to dose a ... RNAi therapeutic being developed for the treatment of transthyretin-mediated amyloidosis ... Read press release ClinicalTrials.gov ... University of London , Richmond Pharmacology is ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 PRC Clinical, ... announced today several management and executive appointments effective immediately. ... Financial Officer (CFO) and member of the Board of ... Business Operations, and Sue Dowden will assume the position ... and current Chief Operations Officer (COO), has been appointed ...
Breaking Biology Technology:Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 2Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 3Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers 4World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3
... Nov. 4 Dr. Juliet Singh,President and Chief Executive ... http://www.transdelpharma.com ), will present at,the Rodman & Renshaw Annual ... City. The Transdel presentation will be given in the,Kennedy ... on Tuesday, November 11th,at 2:25PM EST., To listen ...
... international pharmaceutical services group, reports that its,Functional Sourcing group ... force,for the current fiscal year, representing a continued trend ... growth has included:, -- Doubling the number ... pharmaceutical companies as ranked by Contract Pharma ...
... Children Reach Normal Height, PRINCETON, N.J., Nov. 4 ... from growing to a normal height now have a,new ... origin] injection) for the treatment of short stature in,children ... growth by,age 2-4 years., The U.S. Food and ...
Cached Biology Technology:Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference 2Premier Research Achieves Double-Digit Growth in Functional Sourcing for the Third Straight Year 2FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 2FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 3FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 4FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children 5
(Date:3/10/2015)... , March 10, 2015  NXT-ID, Inc. (NASDAQ: ... the "Company"), a biometric authentication company focused on ... Wocket™ smart wallet has been named the "Number ... Modern. Rethink Modern ( http://www.rethinkmodern.com/ ) ... for your home and lifestyle that have a unique ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , ... today introduced the SentiGaze Software Development Kit ... create applications that use off-the-shelf webcams to track eye ... gazes at a monitor. Heatmaps can be used for ... effectiveness of online advertising. The SDK can also be ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... is available in German . Researchers today ... pumps, and thus specifically control them with light. The Gertrud ... 2012 to four scientists who initiated and were instrumental in ... of the Max Planck Institute of Biophysics in Frankfurt, Karl ...
... , A new fungal species, called , Hebelomagriseopruinatum , ... species. The fungus, whose name can be translated into ... Denmark during a mushroom-hunting tour headed by postdoc Jacob ... mushroom-hunting excursion in 2009, postdoc Jacob Heilman-Clausen from the ...
... In the face of mounting evidence that cancer cells ... and cancer researchers at Rice University, Tel Aviv University ... for outsmarting cancer through its own social intelligence. ... is a random collection of cells running amok," said ...
Cached Biology News:Zülch Prize 2012 for founders of optogenetics 2Zülch Prize 2012 for founders of optogenetics 3Zülch Prize 2012 for founders of optogenetics 4New Danish fungal species discovered 2Experts propose 'cyber war' on cancer 2Experts propose 'cyber war' on cancer 3
The FliTrx Panning Kit is designed to simplify panning for protein-protein interactions with the FliTrx Random Peptide Display Library or the pFliTrx Peptide Display Vector....
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
...
Applications: Western blotting ...
Biology Products: